• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• Structural Organization of the Neurological System
  • Central Nervous System
  • The Brain
  • Spinal Cord
  • Peripheral Nervous System
  • Autonomic Nervous System
  • Neurons and Supportive Cells
  • Neurons
  • Glia
  • Neurotransmitters
  
  
• Aging
• Types of Neurological Diseases and Disorders
• Demographics and Statistics

Chapter Three: Alzheimer’s Disease and Other Dementias

• Overview
• Description of Products
  • Acetylcholinesterase Inhibitors
  • Tacrine (Cognex—First Horizon)
  • Donepezil (Aricept—Eisai)
  • Rivastigmine (Exelon—Novartis)
  • Galanthamine (Reminyl—Janssen Pharmaceutica)
  • N-Methyl-d-aspartate (NMDA)
  • Memantine (Namenda—Forest Labs, Ebixa—Lundbeck)
  • Nootropic Drugs
  • Ergoloid Mesylates (Hydergine—Novartis)
  • Piracetam (Nootropil—UCB Company)
  • Nicergoline (Sermion—Pfizer)
  • Aniracetam (Ampamet—Biogenesis Laboratories)
  
  
• Research and Development
  • Ebixa
  • Alcar
  • Alzhemed
  • Phenserine
  • Xaliproden
  • ABT-890
  • Agilect
  • Avandia
  • CX717
  • Flurizan
  • Leuprolide
  • MEM 3454
  • MKC-231
  • NS2330
  • 189254
  • Phosiphen
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Four: Brain and Neurologic Cancers

• Overview
• Description of Products
  • BCNU (Gliadel Wafer—Guilford Pharmaceuticals)
  • Floxuridine (FUDR—Mayne Pharma; Various Others)
  • Doxorubicin (Adriamycin—Pfizer; Rubex—Bristol-Myers Squibb)
  • Temozolomide (Temodar—Schering)
  
  
• Research and Development
  • Efaproxyn
  • IL-13-PE38
  • TheraCIM
  • TransMID
  • Xerecept
  • Cerepro
  • Cervene
  • Cotara
  • Tarceva
  • Xcytrin
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Five: Brain Trauma and Stroke

• Overview
  • Traumatic Brain Injury
  • Primary Injury
  • Secondary Injury
  • Cerebrovascular Disease and Stroke
  • Ischemic Stroke
  • Hemorrhagic Stroke
  
  
• Description of Products
  • Ticlopidine (Ticlid—Sanofi-Aventis and Roche)
  • Nimodipine (Nimotop—Bayer)
  • Nicergoline (Sermion—Tanabe)
  • tPA (Activase—Genentech)
  
  
• Research and Development
  • Cerovive
  • ReoPro
  • Argatroban
  • Cerebril
  • Desmoteplase
  • NovoSeven
  • SonoLysis
  • Traxoprodil
  • 737004
  • 234551
  • Market Size and Growth
  • Competitive Analysis

Chapter Six: Movement Disorders

• Overview
  • Parkinson’s Disease
  • Huntington’s Disease
  • Myasthenia Gravis
  • Tic and Tourette’s Syndrome
  • Periodic Limb Movement Disorder and Restless Leg Syndrome
  
  
• Description of Products
  • Anticholinergic Agents
  • Biperiden hydrochloride (Akineton—Bristol-Myers Squibb)
  • Trihexyphenidyl HCl (Artane—Wyeth)
  • Benztropine mesylate (Cogentin—Merck)
  • Hyoscyamine sulfate (Levbid—Schwarz)
  • Catechol-O-Methyltransferase Inhibitors
  • Entacapone (Comtan—Novartis)
  • Tolcapone (Tasmar—Valeant Pharmaceuticals/Roche)
  • Dopaminergic Agents
  • Carbidopa (Lodosyn—Bristol-Myers Squibb)
  • Pramipexole (Mirapex—Pfizer and Boehringer Ingelheim)
  • Pergolide (Permax—Amirin)
  • Ropinirole hydrochloride (Requip—GlaxoSmithKline)
  • Carbidopa/Levodopa (Sinemet—Bristol-Myers Squibb)
  • Carbidopa-levodopa (Parcopa—Schwarz)
  • Carbidopa-levodopa (Duodopa—Solvay)
  • Amantadine (Symmetrel—Endo Labs)
  • Bromocriptine (Parlodel—Novartis)
  • Cabergoline (Cabasar—Pfizer)
  • Tetrabenazine (Nitoman—Roche; Xenazine—Cambridge Laboratories)
  • Monoamine Oxidase Inhibitor
  • Selegiline HCl (Eldypryl—Somerset)
  • Selegiline (Zelapar—Valeant Pharmaceuticals)
  • Rasagiline (Azilect—Lundbeck/TEVA)
  • Others
  • Pyridostigmine bromide (Mestinon—Valeant Pharmaceuticals)
  • Edrophonium (Tensilon—Valeant Pharnaceuticals)
  • Ambenonium Chloride (Mytelase—Sanofi-Aventis ) Neostigmine (Prostigmin—Valeant Pharmaceuticals)
  
  
• Research and Development
  • Azilect
  • Neupro
  • Tetrabenazine
  • Zelapar (Selegiline)
  • CEP 1347
  • KW-6002
  • Miraxion
  • Requip CR
  • SLV308
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Seven: Seizure Disorders and Epilepsy

• Overview
  • Generalized Seizures
  • Partial Seizures
  • Aura/Prodrome
  
  
• Description of Products
  • Barbiturates
  • Pentobarbital (Nembutal—Abbott)
  • Benzodiazepines
  • Clonazepam (Klonopin, Rivotril—Roche)
  • Clorazepate (Tranxene—Abbott)
  • Diazepam (Valium—Roche)
  • GABA analogues
  • Tiagabine HCl (Gabitril—Cephalon)
  • Gabapentin (Neurontin—Pfizer)
  • Hydantoins
  • Fosphenytoin sodium (Cerebyx—Pfizer)
  • Phenytoin sodium (Dilantin—Pfizer)
  • Phenytoin (Phenytek—Bertek)
  • Miscellaneous
  • Carbamazepine (Carbatrol—Shire)
  • Valproate sodium (Depacon—Abbott)
  • Valproic acid (Depakene—Abbott)
  • Felbamate (Felbatol—Wallace)
  • Levetiracetam (Keppra—UCB)
  • Carbamazepine (Tegretol—Novartis)
  • Topiramate (Topamax—Ortho-McNeil)
  • Oxcarbazepine (Trileptal—Novartis)
  • Zonisamide (Zonegran—Elan)
  • Phenyltriazines
  • Lamotrigine (Lamictal—GlaxoSmithKline)
  • Succinimides
  • Methsuximide (Celontin—Pfizer)
  • Ethosuximide (Zarontin—Pfizer)
  • Vigabatrin (Sabril—Sanofi-Aventis)
  
  
• Research and Development
  • Keppra (levetiracetam)
  • Lyrica (pregabalin)
  • Topomax (topiramate)
  • Lacosamide
  • Retigabine
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Eight: Spinal Cord and Peripheral Nerve Disorders

• Overview
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis
  • Spinal Cord Injury
  • Guillian-Barre Syndrome
  • Bell’s Palsy
  
  
• Description of Products
  • Interferon Beta (Avonex—Biogen)
  • Interferon Beta-1b (Betaseron—Schering)
  • Glatiramer Acetate (Copaxone—TEVA Neuroscience)
  • Depo-Medrol (Pfizer)
  • Mitoxantrone HCl (Novantrone—Immunex)
  • Prednisolone (Pediapred—Celltech)
  • Interferon Beta (Rebif—Serono)
  • Methylprednisolone sodium succinate (Solu-Medrol—Pfizer)
  • Riluzole (Rilutek—Sanofi-Aventis)
  • Baclofen (Lioresol—Watson) Tizanadine (Zanaflex—Athena)
  
  
• Research and Development
  • Antegren (now called Tysabri)
  • Neurodex
  • Campath-1H
  • Fampridine
  • Mylinax
  • 683699
  • Teriflunomide
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Nine: Other Neurological Conditions and Diseases

• Overview
  • Migraine Headaches
  • Neurofibromatosis
  • Neuropathies
  • Trigeminal Neuralgia
  • Postherpetic Neuralgia
  
  
• Description of Products
  • Serotonin Receptor Agonists
  • Naratriptan (Amerge—GlaxoSmithKline)
  • Sumatriptan (Imitrex—GlaxoSmithKline)
  • Rizatriptan (Maxalt—Merck)
  • Zolmitriptan (Zomig—AstraZeneca )
  • Eletriptan (Relpax—Pfizer)
  • Almotriptan Malate (Axert—Ortho-McNeil Pharmaceutical)
  • Frovatriptan succinate (Frova—Endo)
  • Ergot Alkaloids
  • Ergotamine with Caffeine (Cafergot—Sandoz )
  • Dihydroergotamine mesylate (Migranal—Valeant Pharmaceuticals)
  • Beta Andrenergic Blocking Agents
  • Timolol Maleate (Blocadren—Merck), Propranolol HCl (Inderal—Wyeth)
  • Isometheptene & Others
  • Isometheptene mucate, Dichloralphenazone, Acetaminophen (Midrin—Carnick)
  • Topiramate (Topamax—Johnson & Johnson)
  
  
• Research and Development
  • MT 100
  • MT 300
  • Trexim
  • Acetyl-L-carnitine
  • Botox
  • BIBN4096 BS
  
  
• Market Size and Growth
• Competitive Analysis

Chapter Ten: Issues and Trends Affecting the Neurotherapeutic Drug Market

• Introduction
• Disease Modifying Agents
• Stem Cell Research and Neurological diseases
• BioMarkers
• Early Diagnosis
• Estrogen and Cognitive Function
• Cholesterol and Alzheimer’s Disease
• Nerve Growth Factor Gene Therapy
• Individualized Treatment
• Vitamin Role in Alzheimer’s Disease
• Management of Brain Tumors
• Genetic Therapy
• Alzheimer’s Prevention Initiative

Chapter Eleven: Market Summary

• Overview
• Total Market Size and Forecast

Chapter Twelve: Corporate Profiles

• Introduction
• Abbott Laboratories
• AstraZeneca plc
• Biogen IDEC, Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Eisai, Inc
• GlaxoSmithKline
• Johnson & Johnson Group
• Merck & Company, Inc.
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc.
• Roche
• Sanofi-Aventis
• Schering AG
• Schering-Plough Corporation
• Serono
• TEVA

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: The World Market for Neurotherapeutic Drugs 2002-2009
• Figure 1-1: The World Market for Neurotherapeutic Drugs 2002-2009

Chapter Two: Introduction

• Table 2-1: Neurologic Conditions and Diseases by Chapter in This Study
• Table 2-2: Estimated World Prevalence, Incidence and Mortality of Selected Neurological Conditions and Diseases
• Figure 2-1: Estimated World Prevalence of Top Neurological Conditions and Diseases
• Table 2-3: World Population by Selected Geographical Region (Africa, Asia, Europe, North America, Oceania, South America) 2004-2050
• Figure 2-2: World Population by Selected Geographical Region 2004-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2004
• Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Alzheimer’s Disease and Other Dementias

• Table 3-1: Currently Available Alzheimer’s’s Disease and Dementia Treatments (Type, Brand, and Manufacturer)
• Table 3-2: Alzheimer’s Disease and Other Dementia Therapies in Development
• Table 3-3: The World Market for Alzheimer’s Disease and Other Dementias 2002-2009
• Figure 3-1: Alzheimer’s Disease and Other Dementias Market 2002-2009
• Table 3-4: Alzheimer’s Disease and Other Dementias Market Estimated Products Sales by Geographic Region, 2004
• Figure 3-2: Alzheimer’s Disease and Other Dementias Market Market Share by Geographic Region, 2004
• Table 3-5: Alzheimer’s Disease and Other Dementias Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 3-3: Alzheimer’s Disease and Other Dementias Market Estimated Market Share by Leading Suppliers 2004
• Table 3-6: Alzheimer’s Disease and Other Dementias Market Estimated Sales and Market Share of Top Products 2004
• Figure 3-4: Alzheimer’s Disease and Other Dementias Market Estimated Market Share of Top Products, 2004

Chapter Four: Brain and Neurologic Cancers

• Table 4-1: Currently Available Brain and Neurologic Cancer Treatments
• (Type, Brand, and Manufacturer)
• Table 4-2: Brain and Neurologic Cancer Treatments in Development
• Table 4-3: The Market for Brain and Neurologic Cancer Treatments 2002-2009
• Figure 4-1: Brain and Neurologic Cancer Treatments Market 2002-2009
• Table 4-4: Brain and Neurologic Cancer Treatments Market Estimated Products Sales by Geographic Region, 2004
• Figure 4-2: Brain and Neurologic Cancer Treatments Market Market Share by Geographic Region, 2004
• Table 4-5: Brain and Neurologic Cancer Treatments Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 4-3: Brain and Neurologic Cancer Treatments Market Estimated Market Share by Leading Suppliers 2004
• Table 4-6: Brain and Neurologic Cancer Treatments Market Estimated Sales and Market Share of Top Products 2004
• Figure 4-4: Brain and Neurologic Cancer Treatments Market Estimated Market Share of Top Products, 2004

Chapter Five: Brain Trauma and Stroke

• Table 5-1: Currently Available Brain Trauma and Stroke Treatments (Type,
• Brand, and Manufacturer)
• Table 5-2: Brain Trauma and Stroke Treatments in Development
• Table 5-3: The Market for Brain Trauma and Stroke Treatments 2002-2009 Compound Annual Growth Rate
• Figure 5-1: Brain Trauma and Stroke Treatments Market 2002-2009
• Table 5-4: Brain Trauma and Stroke Treatments Market Estimated Products Sales by Geographic Region, 2004
• Figure 5-2: Brain Trauma and Stroke Treatments Market Market Share by Geographic Region, 2004
• Table 5-5: Brain Trauma and Stroke Treatments Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 5-3: Brain Trauma and Stroke Treatments Market Estimated Market Share by Leading Suppliers 2004

Chapter Six: Movement Disorders

• Table 6-1: Currently Available Movement Disorder Treatments (Type, Brand, and Manufacturer)
• Table 6-2: Movement Disorder Treatments in Development
• Table 6-3: The Market for Movement Disorders 2002-2009
• Figure 6-1: Movement Disorder Market 2002-2009
• Table 6-4: Movement Disorder Market Estimated Products Sales by Geographic Region, 2004
• Figure 6-2: Movement Disorder Market Market Share by Geographic Region, 2004
• Table 6-5: Movement Disorder Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 6-3: Movement Disorder Market Estimated Market Share by Leading Suppliers 2004
• Table 6-6: Movement Disorder Market Estimated Sales of Top Products 2004
• Figure 6-4: Movement Disorder Market Estimated Market Share of Top Products, 2004

Chapter Seven: Seizure Disorders and Epilepsy

• Table 7-1: Currently Available Seizure Disorders and Epilepsy Treatments
• (Type, Brand, and Manufacturer)
• Table 7-2: Seizure Disorders and Epilepsy Treatments in Development
• Table 7-3: The Market for Seizure Disorders and Epilepsy 2002-2009
• Figure 7-1: Seizure Disorders and Epilepsy Market 2002-2009
• Table 7-4: Seizure Disorders and Epilepsy Market Estimated Products Sales by Geographic Region, 2004
• Figure 7-2: Seizure Disorders and Epilepsy Market Market Share by Geographic Region, 2004
• Table 7-5: Seizure Disorders and Epilepsy Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 7-3: Seizure Disorders and Epilepsy Market Estimated Market Share by Leading Suppliers 2004
• Table 7-6: Seizure Disorders and Epilepsy Market Estimated Sales of Top Products 2004
• Figure 7-4: Seizure Disorders and Epilepsy Market Estimated Market Share of Top Products, 2004

Chapter Eight: Spinal Cord and Peripheral Nerve Disorders

• Table 8-1: Currently Available Spinal Cord and Peripheral Nerve Disorder Treatments (Type, Brand, and Manufacturer)
• Table 8-2: Spinal Cord and Peripheral Nerve Disorder Treatments in Development
• Table 8-3: The Market for Spinal Cord and Peripheral Nerve Disorders 2002-2009
• Figure 8-1: Spinal Cord and Peripheral Nerve Disorder Market 2002-2009
• Table 8-4: Spinal Cord and Peripheral Nerve Disorder Market Estimated Products Sales by Geographic Region, 2004
• Figure 8-2: Spinal Cord and Peripheral Nerve Disorder Market Market Share by Geographic Region, 2004
• Table 8-5: Spinal Cord and Peripheral Nerve Disorder Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 8-3: Spinal Cord and Peripheral Nerve Disorder Market Estimated Market Share by Leading Suppliers 2004
• Table 8-6: Spinal Cord and Peripheral Nerve Disorder Market Estimated Sales of Top Products 2004
• Figure 8-4: Spinal Cord and Peripheral Nerve Disorder Market Estimated Market Share of Top Products, 2004

Chapter Nine: Other Neurological Conditions and Diseases

• Table 9-1: Currently Available Other Neurological Conditions and Disorders Treatments (Type, Brand, and Manufacturer)
• Table 9-2: Other Neurological Conditions and Disorders Treatments in Development
• Table 9-3: The Market for Other Neurological Conditions and Disorders 2002-2009
• Figure 9-1: Other Neurological Conditions and Disorders Market 2002-2009
• Table 9-4: Other Neurological Conditions and Disorders Market Estimated Products Sales by Geographic Region, 2004
• Figure 9-2: Other Neurological Conditions and Disorders Market Market Share by Geographic Region, 2004
• Table 9-5: Other Neurological Conditions and Disorders Market Estimated Revenues and Market Share of Leading Suppliers 2004
• Figure 9-3: Other Neurological Conditions and Disorders Market Estimated Market Share by Leading Suppliers 2004
• Table 9-6: Other Neurological Conditions and Disorders Market Estimated Sales of Top Products 2004
• Figure 9-4: Other Neurological Conditions and Disorders Market Estimated Market Share of Top Products, 2004

Chapter Eleven: Market Summary

• Table 11-1: The World Market for Neurotherapeutic Drugs 2002-2009
• Figure 11-1: The World Market for Neurotherapeutic Drugs 2002-2009
• Table 11-2: Worldwide Neurotherapeutic Drug Market by Type 2002-2009
• Figure 11-2: The World Market for Neurotherapeutic Drugs Revenues by Type 2002-2009